The short answer
Yes. Informed consent is legally procedure-specific: it must disclose the material risks, alternatives and expected outcomes of the particular treatment being performed, so a single blanket med spa consent cannot cover filler, neurotoxin, laser, peels and microneedling at once. Use one master registration and policy document plus a distinct signed consent for each procedure, re-consented when the treatment plan, product or provider changes.
Why does a blanket consent fail?
Informed consent is measured against a disclosure standard, and every version of that standard is tied to the specific procedure. Under the professional standard, the question is what a reasonable practitioner in the same situation would disclose about this treatment. Under the reasonable-patient standard — followed in a large share of states and traced back to the D.C. Circuit's reasoning in Canterbury v. Spence — the question is what a prudent patient would want to know about this treatment before deciding.
Neither test can be satisfied by a paragraph saying the patient understands that "aesthetic procedures carry risks." The risk profile of a nasolabial filler injection has nothing in common with the risk profile of a TCA peel. Blindness and skin necrosis from vascular occlusion are material to the first and irrelevant to the second; prolonged post-inflammatory hyperpigmentation and delayed re-epithelialization are material to the second and irrelevant to the first.
The practical test is simple. If a plaintiff's expert can identify a specific complication that a reasonable patient would have wanted to know about, and your form does not name it, you have a consent problem regardless of how carefully the procedure was performed.
What has to be in each procedure consent?
| Element | What it must contain |
|---|---|
| Nature of the procedure | What is being injected or applied, where, and how much |
| Product identity and status | Brand, and whether the use is on-label or off-label |
| Material risks | Named, procedure-specific complications including rare catastrophic ones |
| Alternatives | Other treatments and explicitly the option of no treatment |
| Expected outcome | Realistic result, duration, number of sessions, no guarantee |
| Aftercare and access | Restrictions, warning signs, and how to reach the clinic urgently |
| Who is treating | Name and license type of the person performing the treatment |
| Cost | That correction or complication management may cost extra |
Off-label use deserves its own line. Neurotoxin for masseter slimming, filler in the temples or jawline, and most PRP applications are off-label uses of approved or cleared products. Off-label practice is lawful, but failing to tell the patient the use is off-label is a disclosure failure that is easy for a plaintiff to prove and hard to explain.
When do you have to re-consent?
Consent is not permanent. Re-consent when the product changes, when a new anatomical area is treated, when the dose or depth changes materially, when a different clinician performs the treatment, when the patient's health history changes, and when a complication has occurred and further treatment is planned. Many practices also re-consent annually for ongoing series such as neurotoxin maintenance.
State requirements vary. Some states have informed-consent statutes or board rules covering specific procedures and even mandate particular disclosures; others leave it entirely to common law. Louisiana operates a statutory consent framework with a state medical disclosure panel; Texas has a Medical Disclosure Panel that lists required disclosures for specified procedures; California addresses consent through case law and board guidance; Florida has statutory informed-consent provisions. Check what your board and your state's statute say before assuming common law is the whole picture.
What this means for your paperwork
Structure it in two tiers. Tier one is a master registration and policy packet signed once and refreshed annually: identity, health history attestation, HIPAA acknowledgement, photography and communication consents, financial and cancellation policy. Tier two is a per-procedure consent signed on the day of each treatment and filed with that day's treatment record.
Have the clinician who performs the treatment sign the consent alongside the patient, and add a line noting that questions were invited and answered. Version and date the template, keep superseded versions, and record which version the patient signed. The defensible chart shows the right form, the right version, the right date, and both signatures.
Related questions
This answer is educational and is not legal or medical advice. Requirements vary by state and change over time — verify with your own legal and clinical advisors before applying anything here in practice.